Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 11/20 | 0.41 |
| ▸ | TAS2R8 | Q9NYW2 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131134 | 0.86 | IGF1R (0.41) | IGF1RTAS2R8PPARGPPARDPPARA | |
| SCHEMBL1130926 | 0.86 | IGF1R (0.42) | IGF1RTAS2R8PPARGPPARDPPARA | |
| SCHEMBL1129538 | 0.86 | IGF1R (0.33) | IGF1R | |
| SCHEMBL1131106 | 0.84 | IGF1R (0.40) | IGF1RTAS2R8KDM4ETSHRPPARG | |
| SCHEMBL3472982 | 0.84 | IGF1R (0.40) | IGF1RTAS2R8PPARGPPARDPPARA | |
| SCHEMBL1130411 | 0.84 | IGF1R (0.41) | IGF1RTAS2R8KDM4ETSHRPPARG | |
| SCHEMBL1130303 | 0.82 | IGF1R (0.50) | IGF1RTAS2R8PPARGPPARDPPARA | |
| SCHEMBL1130307 | 0.82 | IGF1R (0.45) | IGF1RTAS2R8 | |
| SCHEMBL1129776 | 0.80 | IGF1R (0.45) | IGF1RTAS2R8 | |
| SCHEMBL1130408 | 0.80 | IGF1R (0.46) | IGF1RTAS2R8PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773808-B1 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2011-02-16 | — | — | EP | disclosed |
| US-7759379-B2 | Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-07-20 | — | — | US | disclosed |
| US-20080004300-A1 | Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004300-A1 | Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | CDK2, CDK1, PRKAR2B | IGF1R 446/4885TAS2R8 2269/4885KDM4E 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.